LPL Financial announced a net income of $357 million for Q3 2026, translating to diluted EPS of $4.52, a significant turnaround from a loss in Q3 2025. The company saw an 11% increase in total client assets to $2.6 trillion and a 16% rise in advisory assets, now comprising 60.9% of total assets. Key strategic initiatives include progressing the Commonwealth Financial Network acquisition, expected to complete in Q4 2026, with an asset retention rate of about 83%. LPL also began rolling out its AI agent Cyan to advisors, signaling innovation in advisor support. The board declared a $0.30 per share dividend, reflecting confidence in ongoing performance and capital management.
LPL Financial's Q3 2026 results provide context for readers following financial sector developments. For readers following the financial sector, here is Pluang's market snapshot as of Oct 28, 2026 03:12 WIB: of 142 priced Financials-sector US stocks tradable on Pluang, 78 rose and 63 fell today. Notable movers include GEMI at USD 3.07 with a 1-day change of +6.97% and 100% sell order activity, HUT at USD 67.29 with a +6.86% change and 96% buy order activity, and WULF at USD 12.71 with a +6.14% change and 60% buy order activity.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
